Your browser doesn't support javascript.
loading
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects.
Qian, Hong-Jie; Wang, Yu; Zhang, Meng-Qi; Xie, Yuan-Chao; Wu, Qing-Qing; Liang, Li-Yu; Cao, Ye; Duan, Hua-Qing; Tian, Guang-Hui; Ma, Juan; Zhang, Zhuo-Bing; Li, Ning; Jia, Jing-Ying; Zhang, Jing; Aisa, Haji Akber; Shen, Jing-Shan; Yu, Chen; Jiang, Hua-Liang; Zhang, Wen-Hong; Wang, Zhen; Liu, Gang-Yi.
Afiliación
  • Qian HJ; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Wang Y; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Zhang MQ; CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Xie YC; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Wu QQ; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Liang LY; CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Cao Y; Lingang Laboratory, Shanghai, 201602, China.
  • Duan HQ; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Tian GH; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Ma J; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Zhang ZB; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Li N; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Jia JY; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Zhang J; Clinical Department, Vigonvita Life Sciences Co., Ltd, Suzhou, 215123, China.
  • Aisa HA; Clinical Department, Vigonvita Life Sciences Co., Ltd, Suzhou, 215123, China.
  • Shen JS; Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China.
  • Yu C; Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China.
  • Jiang HL; Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China.
  • Zhang WH; Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China.
  • Wang Z; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China.
  • Liu GY; Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Acta Pharmacol Sin ; 43(12): 3130-3138, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35296780
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Nucleósidos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Acta Pharmacol Sin Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Nucleósidos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Acta Pharmacol Sin Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China